0001562180-22-001412.txt : 20220211
0001562180-22-001412.hdr.sgml : 20220211
20220211163907
ACCESSION NUMBER: 0001562180-22-001412
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220209
FILED AS OF DATE: 20220211
DATE AS OF CHANGE: 20220211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jones David Scott
CENTRAL INDEX KEY: 0001779458
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 22621849
MAIL ADDRESS:
STREET 1: C/O EYEPOINT PHARMACEUTICALS, INC.,
STREET 2: 480 PLEASANT STREET, SUITE A210
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida Corp.
DATE OF NAME CHANGE: 20080619
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2022-02-09
false
0001314102
EyePoint Pharmaceuticals, Inc.
EYPT
0001779458
Jones David Scott
C/O EYEPOINT PHARMACEUTICALS, INC.
480 PLEASANT STREET
WATERTOWN
MA
02472
false
true
false
false
SVP & Chief Commercial Officer
Common Stock
2022-02-09
4
M
false
4966.00
0.00
A
14097.00
D
Common Stock
2022-02-09
4
F
false
1473.00
10.13
D
12624.00
D
Restricted Stock Units
0.00
2022-02-09
4
A
false
15000.00
0.00
A
Common Stock
15000.00
15000.00
D
Restricted Stock Units
0.00
2022-02-09
4
M
false
4966.00
0.00
D
Common Stock
4966.00
9934.00
D
Stock Option (Right to Buy)
10.13
2022-02-09
4
A
false
60000.00
0.00
A
2032-02-09
Common Stock
60000.00
60000.00
D
Includes 886 shares acquired on July 30, 2021 and 865 shares acquired on January 31,2022 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.
The restricted stock units vest in three ratable annual installments beginning February 9, 2022.
The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.
/s/ Ron Honig, Attorney-in-Fact
2022-02-11